Cover Image
市場調查報告書

醫藥品新興國家市場 (Pharmerging) 趨勢:2016∼2020年

Pharmerging Markets 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 345862
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
醫藥品新興國家市場 (Pharmerging) 趨勢:2016∼2020年 Pharmerging Markets 2016-2020
出版日期: 2015年11月25日 內容資訊: 英文 104 Pages
簡介

新興國家的醫藥品市場估計2016∼2020年,以13%的年複合成長率(CAGR) 成長。新興國家的公共、民間健康保險制度受整備,一般市民的醫藥品取得獲得改善,以及公營、民間、跨國公司和保險企業聯合,構築社會福利一部分的醫療保險體制,成為市場成長的巨大要素。還有各國的宏觀經濟成長和所得增加,政府的輔助計劃的整備和醫療費用支出擴大,也促進市場成長。另一方面,市場細分化,隨著新產品上市、技術開發、企業合併、收購 (M&A) ,市場競爭將更加激化。

本報告提供醫藥品新興國家市場 (Pharmerging) 的現況與未來展望相關分析、市場概要和結構、市場規模趨勢 (今後5年的預測值)、各地區群組 - 層級I (中國)、層級II (巴西、印度、俄羅斯)、層級III (波蘭、阿根廷、土耳其、墨西哥、委內瑞拉、羅馬尼亞、沙烏地阿拉伯、哥倫比亞、越南、南非、阿爾及利亞、泰國、印尼、埃及、巴基斯坦、奈及利亞、烏克蘭) - 詳細趨勢、推動&阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查評估。

第1章 摘要整理

  • 分析結果的概要

第2章 分析範圍

  • 分析概要

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

  • 市場趨勢的概要

第5章 全球醫藥品市場

  • 市場規模與其預測

第6章 醫藥品新興國家 (Pharmerging) 市場

第7章 市場環境

  • 市場規模與其預測
  • 波特的五力分析

第8章 各地區的市場區隔

第9章 層級I各國的市場概要

  • 中國

第10章 層級II各國的市場概要

  • 巴西
  • 俄羅斯
  • 印度

第11章 層級III各國的市場概要

  • 市場規模與其預測

第12章 推動市場要素

  • 公共、私人健康保險
  • 醫療費用支出的增加
  • 各種疾病的發病率的上升
  • 成熟市場上專利懸崖的影響度

第13章 推動因素的影響力

第14章 市場課題

  • 購買能力和市場進入
  • 激烈的市場競爭
  • 不完全的法規政策
  • 價格壓力

第15章 推動因素、課題的影響力

第16章 市場趨勢

  • 策略性的產業聯盟
  • 學名藥的銷售額增加
  • 企業合併、收購 (M&A)
  • 醫藥品在新興國家市場的早期的產品上市

第17章 供應商環境

  • 競爭方案
  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Sanofi
  • 其他卓越供應商

第18章 附錄

  • 簡稱集

第19章 關於Technavio

圖表一覽

目錄
Product Code: IRTNTR7935

Market outlook of the pharmerging markets

Technavios research analyst predicts the pharmerging markets to grow steadily at a CAGR of 13% during the forecast period. The increase in public and private healthcare insurance is the primary growth driver for this market. The governments of various pharmerging countries such as India have implemented several schemes that can be availed by patients to obtain free treatment for different diseases. Also, public and private multinational firms in collaboration with various insurance companies are providing healthcare coverage to their employees as a part of the employee welfare scheme, which is further leveraging people to seek treatment for the existing diseases.

The increase in healthcare spending by governments of pharmerging countries are expected to boost the market growth during the forecast period. Governments and pharmaceutical companies in these regions are making huge investments to improve accessibility to healthcare services, which is primarily driven by rising incomes, macroeconomic expansion, and government-supported policies and programs.

Segmentation and analysis of the pharmerging markets

  • Tier I countries (China)
  • Tier II countries (Brazil, India, and Russia)
  • Tier III countries (Poland, Argentina, Turkey, Mexico, Venezuela, Romania, Saudi Arabia, Colombia, Vietnam, South Africa, Algeria, Thailand, Indonesia, Egypt, Pakistan, Nigeria, and Ukraine)

The Tier I region (China) dominated the market during 2015, with a market share of 45%. An ageing population, increase in healthcare spending, and rise in market opportunities in suburban and rural areas are the main factors fueling the growth of the market in China.

Competitive landscape and key vendors

The pharmerging markets are highly fragmented due to the presence of numerous small and large vendors. Most of the international pharmaceutical companies are facing challenges such as price pressure, regulatory constraints, and competition from local and other international pharmaceutical companies in the pharmerging markets. The competitive environment in the market is expected to intensify with an increase in product extensions, technological innovations, and increase in mergers and acquisitions.

The leading vendors in the market are -

  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Sanofi

Other prominent vendors in the market include Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical, UCB, and Valeant Pharmaceuticals.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020
  • What are the key factors driving the pharmerging markets
  • What are the key market trends impacting the growth of the pharmerging markets
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the vendors in the pharmerging markets
  • Trending factors influencing the market shares of Tier I, Tier II, and Tier III countries
  • What are the key outcomes of the five forces analysis of the pharmerging markets

Technavio also offers customization on reports based on specific client requirement.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Global pharmaceuticals market

  • Market size and forecast

PART 06: Pharmerging markets

PART 07: Market landscape

  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation based on geography

PART 09: Market overview of Tier I countries

  • China

PART 10: Market overview of Tier II countries

  • Brazil
  • Russia
  • India

PART 11: Market overview of Tier III countries

  • Market size and forecast

PART 12: Market drivers

  • Social and private health insurance
  • Increase in healthcare spending
  • High incidence of diseases
  • Impact of patent cliff on mature markets

PART 13: Impact of drivers

PART 14: Market challenges

  • Affordability and access
  • High competition
  • Partial regulatory policies
  • Price pressure

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Strategic alliances
  • Increase in generic sales
  • Mergers and acquisitions
  • Early drug launches in pharmerging markets

PART 17: Vendor landscape

  • Competitive scenario
  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Sanofi
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market 2015-2020 ($ billions)
  • Exhibit 02: Drivers, challenges, and trends in global pharmaceuticals market
  • Exhibit 03: Share of pharmerging markets in global pharmaceuticals market 2015
  • Exhibit 04: Pharmerging markets 2015-2020 ($ billions)
  • Exhibit 05: Shares of pharmerging markets in global pharmaceuticals market 2015-2020
  • Exhibit 06: Shares of Tier I, II, and III countries in pharmerging markets 2015-2020
  • Exhibit 07: Pharmerging market shares by country 2015
  • Exhibit 08: Shares of pharmerging markets in global pharmaceuticals market 2015 and 2020
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Pharmerging markets by geography
  • Exhibit 11: Tier I: Geographical representation
  • Exhibit 12: Major therapy areas by drug sales 2015
  • Exhibit 13: Pharmaceuticals market in China 2015-2020 ($ billions)
  • Exhibit 14: Pharmaceuticals market in China: SWOT analysis
  • Exhibit 15: Geographic representation of Tier II countries
  • Exhibit 16: Pharmaceuticals market in Tier II countries 2015-2020 ($ billions)
  • Exhibit 17: Pharmaceuticals market in Brazil 2015-2020 ($ billions)
  • Exhibit 18: Pharmaceuticals market in Brazil: SWOT analysis
  • Exhibit 19: Pharmaceuticals market in Russia 2015-2020 ($ billions)
  • Exhibit 20: Pharmaceuticals market in Russia: SWOT analysis
  • Exhibit 21: Major therapy areas by drug sales 2015
  • Exhibit 22: Major acquisitions in pharmaceuticals sector in India
  • Exhibit 23: Pharmaceuticals market in India 2015-2020 ($ billions)
  • Exhibit 24: Pharmaceuticals market in India: SWOT analysis
  • Exhibit 25: Geographic representation of Tier III countries
  • Exhibit 26: Pharmaceuticals market in Tier III countries 2015-2020 ($ billions)
  • Exhibit 27: Revenue for select Tier III countries 2015 ($ billions)
  • Exhibit 28: Tier III countries' pharmaceuticals market: SWOT analysis
  • Exhibit 29: Impact of drivers
  • Exhibit 30: Impact of drivers and challenges
  • Exhibit 31: AstraZeneca: Business segmentation based on revenue 2014
  • Exhibit 32: AstraZeneca: Business segmentation based on revenue 2013 and 2014 ($ billions)
  • Exhibit 33: AstraZeneca: Geographical segmentation based on revenue 2014
  • Exhibit 34: AstraZeneca: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
  • Exhibit 35: AstraZeneca: SWOT analysis
  • Exhibit 36: GlaxoSmithKline: Business segmentation based on revenue 2014
  • Exhibit 37: GlaxoSmithKline: Business segmentation based on revenue 2013 and 2014 ($ billions)
  • Exhibit 38: GlaxoSmithKline: Geographical segmentation based on revenue 2014
  • Exhibit 39: GlaxoSmithKline: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
  • Exhibit 40: GlaxoSmithKline: SWOT analysis
  • Exhibit 41: Merck: Business segmentation based on revenue 2014
  • Exhibit 42: Merck: Business segmentation based on revenue 2013 and 2014 ($ billions)
  • Exhibit 43: Merck: Geographical segmentation based on revenue 2014
  • Exhibit 44: Merck: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
  • Exhibit 45: Merck: SWOT analysis
  • Exhibit 46: Novartis: Business segmentation based on revenue 2014
  • Exhibit 47: Novartis: Business segmentation based on revenue 2013 and 2014 ($ billions)
  • Exhibit 48: Novartis: Geographical segmentation based on revenue 2014
  • Exhibit 49: Novartis: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ millions)
  • Exhibit 50: Novartis :SWOT analysis
  • Exhibit 51: Pfizer: Business segmentation based on revenue 2014
  • Exhibit 52: Pfizer: Business segmentation based on revenue 2013 and 2014 ($ billions)
  • Exhibit 53: Pfizer: Geographical segmentation based on revenue 2014
  • Exhibit 54: Pfizer: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
  • Exhibit 55: Pfizer: SWOT analysis
  • Exhibit 56: Sanofi: Business segmentation based on revenue 2014
  • Exhibit 57: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 58: Sanofi: Geographical segmentation based on revenue 2014
  • Exhibit 59: Sanofi: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
  • Exhibit 60: Sanofi: SWOT analysis
Back to Top